文献速递造血干细胞移植与细胞治疗白血病

比较非缓解期急性髓系白血病的脐带血移植与同胞相合供者移植

Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia.
PubMed 文献 · Leukemia · 2021-11-24

该研究纳入2009年1月至2018年12月间2451例非缓解期复发/难治性急性髓系白血病成人患者,其中脐带血移植1738例、同胞相合供者移植713例,采用倾向性评分匹配分析。匹配后脐带血移植组5年无进展生存率为25.2%,同胞相合供者移植组为18.1%(P=0.009),校正后风险比为0.83(95%CI:0.69-1.00,P=0.045)。

要点

  • 非缓解期复发/难治性急性髓系白血病成人中,脐带血移植1738例、同胞相合供者移植713例。
  • 倾向性评分匹配后,脐带血移植组5年无进展生存率25.2% vs 同胞相合供者移植组18.1%(P=0.009)。
  • 校正后风险比0.83(95%CI:0.69-1.00,P=0.045),复发风险比为0.78(95%CI:0.69-0.89,P<0.001)。

核心结论

  • 在该非缓解期复发/难治性急性髓系白血病成人群体中,异基因造血干细胞移植后脐带血移植与同胞相合供者移植相比,与更好的5年无进展生存相关。

研究设计与样本

  • 研究纳入2009年1月至2018年12月间2451例非缓解期复发/难治性急性髓系白血病成人患者,其中接受脐带血移植1738例、接受同胞相合供者移植713例。
  • 采用倾向性评分匹配分析评估5年无进展生存及脐带血移植的预后影响;匹配后两组患者特征均衡。

主要发现

  • 倾向性评分匹配后,脐带血移植组5年无进展生存率为25.2%(95%CI:21.2-29.5%),同胞相合供者移植组为18.1%(95%CI:14.5-22.0%)(P=0.009)。
  • 校正后风险比为0.83(95%CI:0.69-1.00,P=0.045)。
  • 复发风险比为0.78(95%CI:0.69-0.89,P<0.001),非复发死亡风险比为1.42(95%CI:1.15-1.76,P=0.001)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cord blood transplantation (CBT) is an alternative donor transplantation method and has the advantages of rapid availability and the possibility of inducing a more potent graft-versus-leukemia effect, leading to a lower relapse rate for patients with non-remission relapse and refractory acute myeloid leukemia (R/R AML). This study aimed to investigate the impact of CBT, compared to human leukocyte antigen-matched related donor transplantation (MRDT). This study included 2451 adult patients with non-remission R/R AML who received CBT (1738 patients) or MRDT (713 patients) between January 2009 and December 2018. Five-year progression-free survival (PFS) and the prognostic impact of CBT were evaluated using a propensity score (PS) matching analysis. After PS matching, the patient characteristics were well balanced between the groups. The five-year PFS was 25.2% (95% confidence interval [CI]: 21.2-29.5%) in the CBT group and 18.1% (95% CI: 14.5-22.0%) in the MRDT group (P = 0.009). The adjusted hazard ratio (HR) was 0.83 (95% CI: 0.69-1.00, P = 0.045); this was due to a more pronounced decrease in the relapse rate (HR: 0.78, 95% CI: 0.69-0.89, P < 0.001) than an increase in the NRM (1.42, 1.15-1.76, P = 0.001). In this population, CBT was associated with a better 5-year PFS than MRDT after allogeneic HSCT.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Shimomura Y, Sobue T, Hirabayashi S, et al. Comparing cord blood transplantation and matched related donor transplantation in non-remission acute myeloid leukemia. Leukemia. 2021. PMID: 34815516. doi:10.1038/s41375-021-01474-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。